title: Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis.
abstract: LPA (lysophosphatidic acid, 1-acyl-2-hydroxy-sn-glycero-3-phosphate), is a growth factor-like lipid mediator that regulates many cellular functions, many of which are unique to malignantly transformed cells. The simple chemical structure of LPA and its profound effects in cancer cells has attracted the attention of the cancer therapeutics field and drives the development of therapeutics based on the LPA scaffold. In biological fluids, LPA is generated by ATX (autotaxin), a lysophospholipase D that cleaves the choline/serine headgroup from lysophosphatidylcholine and lysophosphatidylserine to generate LPA. In the present article, we review some of the key findings that make the ATX-LPA signalling axis an emerging target for cancer therapy.
authors.affiliation: Department of Physiology, College of Medicine, University of Tennessee Health Science Center, 894 Union Avenue, Memphis, TN 38163, USA.
authors.forename: Mari
authors.initials: M
authors.lastname: Gotoh
authors.forename: Yuko
authors.initials: Y
authors.lastname: Fujiwara
authors.forename: Junming
authors.initials: J
authors.lastname: Yue
authors.forename: Jianxiong
authors.initials: J
authors.lastname: Liu
authors.forename: SueChin
authors.initials: S
authors.lastname: Lee
authors.forename: James
authors.initials: J
authors.lastname: Fells
authors.forename: Ayako
authors.initials: A
authors.lastname: Uchiyama
authors.forename: Kimiko
authors.initials: K
authors.lastname: Murakami-Murofushi
authors.forename: Stephen
authors.initials: S
authors.lastname: Kennel
authors.forename: Jonathan
authors.initials: J
authors.lastname: Wall
authors.forename: Renukadevi
authors.initials: R
authors.lastname: Patil
authors.forename: Renuka
authors.initials: R
authors.lastname: Gupte
authors.forename: Louisa
authors.initials: L
authors.lastname: Balazs
authors.forename: Duane D
authors.initials: DD
authors.lastname: Miller
authors.forename: Gabor J
authors.initials: GJ
authors.lastname: Tigyi
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008246:Lysophospholipids / Q000378:metabolism; D058990:Molecular Targeted Therapy; D009361:Neoplasm Invasiveness; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D063065:Organophosphonates / Q000494:pharmacology / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D010727:Phosphoric Diester Hydrolases / Q000235:genetics / Q000378:metabolism*; D049368:Receptors, Lysophosphatidic Acid / Q000378:metabolism*; D015398:Signal Transduction; D023041:Xenograft Model Antitumor Assays; D000099189:Lysophospholipase D
chemical_list: D000970:Antineoplastic Agents; D008246:Lysophospholipids; D063065:Organophosphonates; D010726:Phosphodiesterase Inhibitors; D010727:Phosphoric Diester Hydrolases; D049368:Receptors, Lysophosphatidic Acid; D000099189:Lysophospholipase D; C560360:4-pentadecylbenzylphosphonic acid; C032881:lysophosphatidic acid